500 related articles for article (PubMed ID: 31411531)
1. Impact of Fc N-glycan sialylation on IgG structure.
Zhang Z; Shah B; Richardson J
MAbs; 2019; 11(8):1381-1390. PubMed ID: 31411531
[TBL] [Abstract][Full Text] [Related]
2. Effect of Fc-Glycan Structure on the Conformational Stability of IgG Revealed by Hydrogen/Deuterium Exchange and Limited Proteolysis.
Fang J; Richardson J; Du Z; Zhang Z
Biochemistry; 2016 Feb; 55(6):860-8. PubMed ID: 26812426
[TBL] [Abstract][Full Text] [Related]
3. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
4. Understanding of decreased sialylation of Fc-fusion protein in hyperosmotic recombinant Chinese hamster ovary cell culture: N-glycosylation gene expression and N-linked glycan antennary profile.
Lee JH; Jeong YR; Kim YG; Lee GM
Biotechnol Bioeng; 2017 Aug; 114(8):1721-1732. PubMed ID: 28266015
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.
Mimura Y; Kelly RM; Unwin L; Albrecht S; Jefferis R; Goodall M; Mizukami Y; Mimura-Kimura Y; Matsumoto T; Ueoka H; Rudd PM
J Immunol Methods; 2016 Jan; 428():30-6. PubMed ID: 26627984
[TBL] [Abstract][Full Text] [Related]
6. Production of α2,6-sialylated IgG1 in CHO cells.
Raymond C; Robotham A; Spearman M; Butler M; Kelly J; Durocher Y
MAbs; 2015; 7(3):571-83. PubMed ID: 25875452
[TBL] [Abstract][Full Text] [Related]
7. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins.
Ahmed AA; Giddens J; Pincetic A; Lomino JV; Ravetch JV; Wang LX; Bjorkman PJ
J Mol Biol; 2014 Sep; 426(18):3166-3179. PubMed ID: 25036289
[TBL] [Abstract][Full Text] [Related]
8. Integrated Genome and Protein Editing Swaps α-2,6 Sialylation for α-2,3 Sialic Acid on Recombinant Antibodies from CHO.
Chung CY; Wang Q; Yang S; Yin B; Zhang H; Betenbaugh M
Biotechnol J; 2017 Feb; 12(2):. PubMed ID: 27943633
[TBL] [Abstract][Full Text] [Related]
9. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.
Blundell PA; Le NPL; Allen J; Watanabe Y; Pleass RJ
J Biol Chem; 2017 Aug; 292(31):12994-13007. PubMed ID: 28620050
[TBL] [Abstract][Full Text] [Related]
10. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
11. An atomistic perspective on antibody-dependent cellular cytotoxicity quenching by core-fucosylation of IgG1 Fc N-glycans from enhanced sampling molecular dynamics.
Harbison A; Fadda E
Glycobiology; 2020 May; 30(6):407-414. PubMed ID: 31829411
[TBL] [Abstract][Full Text] [Related]
12. Sequence-to-structure dependence of isolated IgG Fc complex biantennary N-glycans: a molecular dynamics study.
Harbison AM; Brosnan LP; Fenlon K; Fadda E
Glycobiology; 2019 Jan; 29(1):94-103. PubMed ID: 30325416
[TBL] [Abstract][Full Text] [Related]
13. Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
Raju TS
Curr Opin Immunol; 2008 Aug; 20(4):471-8. PubMed ID: 18606225
[TBL] [Abstract][Full Text] [Related]
14. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions.
Mattu TS; Pleass RJ; Willis AC; Kilian M; Wormald MR; Lellouch AC; Rudd PM; Woof JM; Dwek RA
J Biol Chem; 1998 Jan; 273(4):2260-72. PubMed ID: 9442070
[TBL] [Abstract][Full Text] [Related]
15. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods.
Reusch D; Haberger M; Falck D; Peter B; Maier B; Gassner J; Hook M; Wagner K; Bonnington L; Bulau P; Wuhrer M
MAbs; 2015; 7(4):732-42. PubMed ID: 25996192
[TBL] [Abstract][Full Text] [Related]
16. Lectin analysis of human immunoglobulin G N-glycan sialylation.
Dalziel M; McFarlane I; Axford JS
Glycoconj J; 1999 Dec; 16(12):801-7. PubMed ID: 11133020
[TBL] [Abstract][Full Text] [Related]
17. Engineering host cell lines to reduce terminal sialylation of secreted antibodies.
Naso MF; Tam SH; Scallon BJ; Raju TS
MAbs; 2010; 2(5):519-27. PubMed ID: 20716959
[TBL] [Abstract][Full Text] [Related]
18. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.
Scallon BJ; Tam SH; McCarthy SG; Cai AN; Raju TS
Mol Immunol; 2007 Mar; 44(7):1524-34. PubMed ID: 17045339
[TBL] [Abstract][Full Text] [Related]
19. Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase.
Jassal R; Jenkins N; Charlwood J; Camilleri P; Jefferis R; Lund J
Biochem Biophys Res Commun; 2001 Aug; 286(2):243-9. PubMed ID: 11500028
[TBL] [Abstract][Full Text] [Related]
20. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]